

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Ashkenazi et al.)	Group Art Unit: Unknown
)	
App. No.	:	09 978,564)	
)	
Filed	:	October 16, 2001)	
)	
For	:	SECRETED AND)	
		TRANSMEMBRANE)	
		POLYPEPTIDES AND)	
		NUCLEIC ACIDS ENCODING)	
		THE SAME)	
)	
Examiner	:	Unknown)	

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
PO Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing 2 references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 20, 2002

By: _____
Ginger R. Dreger
Registration No. 33,055
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
GNE 2630P1C25

APPLICATION NO. 09/978,564

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY

APPLICANT
Askenazi et alFILING DATE
October 16, 2001GROUP
Unknown

EXAMINER INITIAL	OTHER DOCUMENTS INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.	
	1	Blast Results A1-A12 (Alignment of DNA45419 and various nucleotide sequences - GenBank Database), October 4, 2001
	2	Blast Results B1-B7 (Alignment of DNA45419 and various polypeptide sequences - Dayhoff Database), October 3, 2001
	3	
	4	
	5	

W:\DOCS\BGY\BGY-2150\DOC
031902

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	